Dr Reddys LaboratoriesNSE: DRREDDYBSE: 500124Healthcare · Pharmaceuticals

₹1,148.103.30 (0.29%)

Mkt Cap: ₹95,670.54 Cr.
P/E (TTM): 29.64
Open: ₹1,152.00
Day's Range: ₹1,141.70 – ₹1,154.30
52W Range: ₹1,101.00 – ₹1,414.90
Div Yield: 0.7%
EPS (TTM): ₹39.75
Book Value: ₹460.31

Dr Reddys Laboratories Financial Statements

Name: Dr Reddys Laboratories Financials — historical data
Creator: StockeZee

For Mar 2026, Dr Reddys Laboratories reported revenue of ₹33,700 crore and net profit of ₹4,196 crore. Return on equity stands at 11.20%. Profit & loss, balance sheet and cash flow across 9 reported years are below.

Updated 31 Jul 2026Source: NSE & BSE company filingsNifty 50 constituent

Latest year revenue: ₹33,700 Cr
EBITDA: ₹6,454 Cr
Operating margin: 19.15%
Profit after tax: ₹4,196 Cr
Net margin: 12.45%
EPS: ₹50.27
Latest year: Mar 2026
Years reported: 9

Dr Reddys Laboratories profit & loss

Reported annual performance for Dr Reddys Laboratories, oldest to newest. Figures in ₹ crore unless a row states otherwise.

Dr Reddys Laboratories annual profit and loss statement. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue from Operations	14,281	15,448	17,517	19,048	21,545	24,670	28,011	32,644	33,700
Sales Growth YoY %	—	8.17%	13.39%	8.74%	13.11%	14.5%	13.54%	16.54%	3.24%
Other Income	155	338	621	291	484	1,056	894	1,097	1,358
Total Income	14,436	15,786	18,138	19,339	22,030	25,725	28,905	33,741	35,059
Cost of Goods Sold (COGS)	4,040	4,495	5,554	6,079	7,442	7,658	8,209	9,980	12,239
Cost of Materials Consumed	2,631	2,889	2,985	4,296	4,312	4,220	4,490	5,684	6,501
Purchases of Stock-in-Trade	1,450	1,881	2,546	2,574	3,484	3,367	4,399	4,841	6,162
Changes in Inventories	-42	-275	24	-791	-354	71	-681	-545	-424
Gross Profit	10,242	10,953	11,963	12,969	14,103	17,012	19,802	22,664	21,461
Gross Margin %	71.71%	70.9%	68.29%	68.09%	65.46%	68.96%	70.69%	69.43%	63.68%
Total Operating Expenses	7,890	7,775	9,492	9,099	10,335	10,663	11,869	14,117	15,008
Employee Benefit Expense	3,215	3,356	3,380	3,630	3,886	4,647	5,030	5,580	5,991
Other Expenses	4,675	4,419	6,112	5,469	6,450	6,016	6,839	8,537	9,017
EBITDA	2,351	3,178	2,470	3,870	3,768	6,349	7,933	8,547	6,454
OPM %	16.46%	20.57%	14.1%	20.32%	17.49%	25.74%	28.32%	26.18%	19.15%
Total Non-Operating Expenses	1,156	1,224	1,261	1,326	1,261	1,393	1,641	1,987	2,433
Depreciation & Amortisation	1,077	1,135	1,163	1,229	1,165	1,250	1,470	1,704	2,059
Finance Costs	79	89	98	97	96	143	171	283	374
Profit Before Tax (PBT)	1,350	2,292	1,830	2,836	2,991	6,012	7,186	7,658	5,379
Tax Expense	438	386	-140	932	879	1,541	1,623	1,954	1,235
Current Tax	175	471	662	817	1,101	814	1,946	2,258	1,395
Deferred Tax	263	-85	-802	115	-222	727	-323	-304	-159
Effective Tax %	32.43%	16.83%	-7.67%	32.87%	29.38%	25.64%	22.59%	25.52%	22.96%
Total Profit for Period	947	1,950	2,026	1,952	2,183	4,507	5,578	5,725	4,158
Less: Non-controlling Interests	0	0	0	0	0	0	0	70	-38
Net Profit (Owner's PAT)	947	1,950	2,026	1,952	2,183	4,507	5,578	5,655	4,196
Net Profit Margin %	6.63%	12.62%	11.57%	10.25%	10.13%	18.27%	19.91%	17.32%	12.45%
PAT Growth YoY %	—	105.96%	3.9%	-3.67%	11.83%	106.52%	23.75%	1.38%	-25.8%
Earnings Per Share (EPS)	₹11.41	₹23.48	₹24.38	₹23.47	₹26.23	₹54.13	₹66.87	₹67.77	₹50.27
Diluted Shares Outstanding (Cr.)	83	83	83	83	83	83	83	83	83
Profit/Loss from Associates	34	44	56	48	70	37	15	22	13
Other Comprehensive Income (Net of Tax)	-284	-109	-65	540	-290	-12	-66	205	740
Expenses	13,086	13,494	16,308	16,503	19,039	19,714	21,719	26,083	29,679
Material Cost %	18.42%	18.7%	17.04%	22.55%	20.02%	17.11%	16.03%	17.41%	19.29%
Employee Cost %	22.51%	21.73%	19.3%	19.06%	18.04%	18.84%	17.96%	17.09%	17.78%
Other Cost %	32.74%	28.61%	34.89%	28.71%	29.93%	24.39%	24.42%	26.15%	26.76%
Interest Coverage (x)	16.17	22.99	13.3	27.23	27.17	35.71	37.77	24.19	11.76

Dr Reddys Laboratories revenue and profit trend

Reported annual revenue and net profit, oldest to newest. Two panels because the two measures live on different scales — one shared axis would distort both.

Dr Reddys Laboratories balance sheet

Assets, liabilities and shareholders' equity as reported, in Schedule III order. Figures in ₹ crore unless a row states otherwise.

Dr Reddys Laboratories annual balance sheet with assets, liabilities and equity. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Equity	14,024	15,599	17,642	19,212	23,286	28,255	33,927	38,231
Equity Share Capital	83	83	83	83	83	83	83	84
Reserves & Surplus	13,941	15,516	17,559	19,129	23,203	28,171	33,466	37,808
Equity Method Investments	253	276	338	432	470	420	481	567
Total Equity	14,024	15,599	17,642	19,212	23,286	28,255	33,927	38,231
Non-Current Liabilities	2,545	412	871	769	427	1,021	2,465	3,145
Long-term Borrowings	2,200	130	630	575	128	380	380	—
Deferred Tax Liabilities	47	2	29	1	76	84	1,404	1,547
Non-Current Provisions	79	75	51	26	20	24	30	34
Other Non-Current Liabilities	208	206	162	167	203	314	226	301
Non-Current Financial Liabilities	2,210	130	630	575	128	599	806	1,264
Current Liabilities	5,897	7,214	8,104	9,766	8,572	9,588	13,034	16,747
Short-term Borrowings	1,213	1,653	2,315	2,708	1,219	1,272	3,805	6,294
Trade Payables	1,367	1,525	1,811	2,266	2,268	2,614	2,648	3,038
Current Financial Liabilities	4,853	6,039	6,586	7,607	6,419	7,518	10,636	14,250
Other Current Financial Liabilities	2,274	2,861	2,461	2,633	2,931	3,632	4,184	4,919
Other Current Liabilities	547	651	877	1,028	1,286	1,144	1,319	1,192
Current Provisions	479	467	502	587	653	692	776	870
Current Tax Liabilities	18	57	139	544	214	234	303	435
Total Liabilities	8,442	7,627	8,975	10,535	8,999	10,609	15,499	19,893
Total Non-Current Assets	11,016	10,188	11,792	11,636	11,591	14,059	24,409	27,944
Property, Plant & Equipment (PPE)	4,913	4,778	4,732	4,887	5,654	6,249	7,298	10,078
Capital Work-in-Progress	473	436	954	1,280	975	1,351	2,399	1,460
Intangible Assets	1,812	1,581	2,914	2,687	3,018	3,627	9,614	10,506
Non-Current Investments	81	33	496	167	66	106	239	894
Other Non-Current Assets	41	21	31	63	28	509	276	448
Non-Current Financial Assets	166	286	584	450	139	227	1,127	1,186
Net Fixed Assets	7,198	6,795	8,600	8,854	9,647	11,227	19,312	22,044
Total Current Assets	11,450	13,037	14,810	18,111	20,694	24,805	25,018	30,179
Inventories	3,358	3,507	4,541	5,088	4,867	6,355	7,109	7,653
Trade Receivables	3,987	5,028	4,964	6,676	7,249	8,030	9,042	10,123
Cash & Cash Equivalents	223	205	1,483	1,485	578	711	1,465	1,537
Current Investments	2,253	2,369	1,974	2,017	4,450	4,405	3,331	3,823
Current Financial Assets	6,710	8,050	8,729	11,461	14,047	16,432	15,203	19,536
Other Current Assets	1,042	1,042	1,265	1,233	1,512	2,018	2,707	2,990
Other Current Financial Assets	247	448	308	348	618	2,270	370	2,241
Assets Held for Sale	—	—	15	—	—	—	—	—
Current Tax Assets	340	438	275	329	269	—	—	—
Net Working Capital	5,553	5,823	6,706	8,345	12,122	15,217	11,984	13,432
Additional Asset Fields	432	1,220	1,069	1,277	705	1,058	2,210	2,558
Def Tax Assets	432	1,220	1,069	1,277	705	1,058	1,833	2,219
Non Controlling Int	—	—	—	—	—	—	378	339
Total Assets	22,466	23,225	26,617	29,747	32,285	38,864	49,427	58,123
Total Borrowings	3,413	1,784	2,944	3,283	1,347	1,652	4,185	6,294
Net Debt	3,190	1,578	1,462	1,798	769	942	2,719	4,757
Debt to Equity (x)	0.24	0.11	0.17	0.17	0.06	0.06	0.12	0.16
Current Ratio (x)	1.94	1.81	1.83	1.85	2.41	2.59	1.92	1.8

Dr Reddys Laboratories cash flow statement

Cash generated and used across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.

Dr Reddys Laboratories annual cash flow statement across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Cash from Operating Activities	2,811	5,887	4,543	4,643	5,674
Profit Before Tax	2,991	6,012	7,186	7,658	5,379
Depreciation & Amortisation	1,165	1,250	1,470	1,704	2,059
Finance Costs	96	143	171	283	374
Working Capital Changes	-1,382	-786	-1,662	-2,477	-323
Tax Paid	-744	-1,071	-2,005	-1,999	-1,353
Net Cash from Investing Activities	-2,639	-4,137	-4,028	-5,102	-6,549
Purchase of PPE	-1,466	-1,132	-1,640	-2,750	-2,331
Sale of Fixed Assets	332	8	109	124	171
Interest Received	87	78	134	337	152
Net Cash from Financing Activities	-242	-2,686	-376	1,186	829
Proceeds from Borrowings	352	0	929	2,449	2,026
Repayment of Borrowings	0	-1,938	-380	0	-0
Interest Paid	-135	-185	-227	-348	-444
Dividend Paid	-415	-498	-665	-666	-666
Buyback / Redemption of Shares	0	0	0	-139	0
Lease Liabilities Paid	-79	-102	-115	-129	-126
Net Change in Cash	3	-907	133	749	78
Effect of Foreign Exchange Changes	73	29	-6	22	124
Free Cash Flow	1,345	4,755	2,903	1,892	3,343
CFO / PBT (x)	0.94	0.98	0.63	0.61	1.05

Dr Reddys Laboratories key ratios

Valuation, profitability, return, leverage and per-share measures computed from reported statements — not from adjusted or normalised earnings.

Dr Reddys Laboratories trades at a P/E of 29.64× against a sector median of 42.68× — a 31% discount. Sector comparisons can mislead for conglomerates with mixed business lines.

Dr Reddys Laboratories valuation, profitability, return and leverage ratios
Ratio	Category	Value
P/E (TTM)	Valuation	29.64
Forward P/E	Valuation	20.22
P/B	Valuation	2.52
PEG (TTM)	Valuation	1.59
EV / EBITDA (TTM)	Valuation	13.49
P/S (TTM)	Valuation	2.88
Operating margin	Profitability	19.2%
Net margin (TTM)	Profitability	12.76%
Return on equity	Return ratios	11.2%
Return on capital employed	Return ratios	13%
Return on assets	Return ratios	5.74%
Debt to equity	Leverage & liquidity	0.2
Beta	Leverage & liquidity	0.52
EPS (TTM)	Per share	₹39.75
Book value	Per share	₹460.31
Revenue / share (TTM)	Per share	₹403.42
Cash flow / share	Per share	₹68.16
Dividend yield	Shareholder returns	0.7%
Dividend payout (TTM)	Shareholder returns	15.56%

How this is calculated

Statements are as filed with the exchanges. Consolidated figures are shown where reported. Figures are in rupees crore unless the table states otherwise. Ratios are computed from the same reported statements, not from adjusted or normalised earnings.

Index membership reflects the Nifty 100 as published by NSE Indices, effective 2026-03-30.

Dr Reddys Laboratories: frequently asked questions

What is Dr Reddys Laboratories's annual revenue?

Dr Reddys Laboratories reported revenue of ₹33,700 crore in Mar 2026, up 3.2% on the previous financial year.

Is Dr Reddys Laboratories profitable?

Dr Reddys Laboratories reported a net profit of ₹4,196 crore in Mar 2026, down 25.8% on the previous financial year.

What is Dr Reddys Laboratories's EPS?

Dr Reddys Laboratories reported earnings per share of ₹50.27 for Mar 2026.

What is Dr Reddys Laboratories's operating margin?

Dr Reddys Laboratories's operating margin for Mar 2026 was 19.15%.

What is Dr Reddys Laboratories's return on equity?

Dr Reddys Laboratories's return on equity stands at 11.20%. ROE measures profit generated per rupee of shareholder equity.

How many years of Dr Reddys Laboratories financials are shown?

9 reported financial years are tabulated on this page, the most recent being Mar 2026.

Are these figures consolidated or standalone?

Consolidated figures are shown wherever the company reports them, and standalone otherwise. The basis in use is labelled on the statement table.

More Dr Reddys Laboratories data

Compare financial statements with peers

Explore

Comparing financial statements across companies is more useful than reading one in isolation — the peer links above open the same view for Dr Reddys Laboratories’s closest listed competitors.

Disclaimer

The data, ratios and commentary about Dr Reddys Laboratories Ltd (DRREDDY) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.